CClinicalTrials.gg
RecruitingNCT06914349Updated Jun 6, 2025

Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure

An interventional study of Antecolic gastrojejunostomy and Retrocolic gastrojejunostomy in Pancreatic Cancer Resectable and Pancreas Neoplasms, sponsored by University of Thessaly. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by University of Thessaly · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Aim: This randomized clinical study aims to compare occurrence of DGE in patients undergoing either antecolic or retrocolic gastrojejunostomy following pancreaticoduodenectomy.

Methods: Participants of this study will be patients undergoing pylorus preserving pancreaticoduodenectomy at the Surgical Department of the University Hospital of Larissa. Patients will be randomized to undergo either an antecolic or a retrocolic gastrojejunostomy and the occurrence of DGE will then be compared between the two groups. Individuals younger than 18 or older than 75 years old, as well as patients who do not consent to participate in this trial, will be excluded.

Expected results: Based on available literature, antecolic gastrojejunostomy may be related with a lower incidence of DGE, without a statistically significant difference between the two methods. We aim to show if one of the two methods of gastrointestinal reconstruction (antecolic versus retrocolic) affects DGE.

02

Conditions studied

  • Pancreatic Cancer Resectable
  • Pancreas Neoplasms

Keywords

  • Gastrojejunostomy
  • Whipple's
  • Antecolic
  • Retrocolic
03

In context

Pancreatic Neoplasms

3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.

This study's planned enrollment of 76 is above the median of 46 across 2,424 interventional studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

University of Thessaly is the lead sponsor of 188 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age over 18 years old
  • Elective pancreaticoduodenectomy
  • Signed consent form

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years old
  • Patients who are participants in other trials that may affect the results of this study
  • Patients who do not consent to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
76 participants (estimated)

Study arms

  • Active comparator
    Antecolic gastrojejunostomy

    Procedure: Antecolic gastrojejunostomy

  • Active comparator
    Retrocolic gastrojejunostomy

    Procedure: Retrocolic gastrojejunostomy

Interventions

  • ProcedureAntecolic gastrojejunostomy

    Gastrojejunostomy in front of the transverse colon

  • ProcedureRetrocolic gastrojejunostomy

    Gastrojejunostomy through the transverse mesocolon

06

What researchers measure

Primary outcomes

  1. Delayed Gastric Emptying

    The occurence of delayed gastric emptying will be compared between two groups of patients: those who undergo an antecolic gastrojejunostomy and those who undergo a retrocolic approach.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • University of Thessaly
    Larissa, 41500, Greece
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06914349
Lead sponsor
University of Thessaly
Responsible party
Chrysoula-Christina Kolla (MD, Msc, University of Thessaly) — Principal investigator
First posted
Apr 6, 2025
Start date
Mar 30, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Jun 6, 2025

Study contacts

Chrysoula C Kolla
Contact
christinakolla@yahoo.gr
+306983075706
Dimitrios Symeonidis
study chair · University of Thessaly

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion